• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2003年至2022年重症肌无力的当前趋势和热点图谱:一项文献计量分析

Mapping current trends and hotspots in myasthenia gravis from 2003 to 2022: a bibliometric analysis.

作者信息

Tian Yukun, Shen Qiqi, Peng Siyang, Meng Linghao, Fang Ruiying, Xiong Anni, Li Shaohong, Yang Yajing, Chang Weiqian, Ni Jinxia, Zhu Wenzeng

机构信息

Department of Acupuncture, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.

Treatment Center of Traditional Chinese Medicine Bo'ai Hospital, China Rehabilitation Research Center, Beijing, China.

出版信息

Front Neurol. 2023 Dec 28;14:1320344. doi: 10.3389/fneur.2023.1320344. eCollection 2023.

DOI:10.3389/fneur.2023.1320344
PMID:38213833
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10782526/
Abstract

INTRODUCTION

Research on myasthenia gravis (MG) has undergone rapid development in recent years. This article aimed to elucidate the characteristics of MG publications over the past 20 years and analyze emerging trends using bibliometric methods.

METHODS

Information on MG articles was obtained from the Web of Science Core Collection and stored in Excel for quantitative analyses. Bibliometric analyses were performed using CiteSpace and VOSviewer to visualize publications according to countries/regions, institutions, journals, and authors.

RESULTS

A total of 3,610 publications were included in the analysis. The USA had the highest number of publications (NP) and H-index. Among the institutions, the University of Oxford had the highest NP, followed by the University of Toronto and Duke University. Close cooperation was observed among countries and institutions. The most productive author was Renato Mantegazza, followed by Jan J. Verschuuren, and Amelia Evoli. published the most articles on MG, followed by the and . The keyword with the highest strength is "neuromuscular transmission," followed by "safety" and "rituximab." Co-citation analysis includes 103 publications cited at least 65 times, categorized into four clusters. Additionally, 123 keywords cited more than 40 times were analyzed and divided into five clusters.

CONCLUSION

This bibliometric analysis shows the framework of research over the past 20 years by mapping the scholarly contributions of various countries or regions, institutions, journals, and authors in MG. The analysis also explores future trends and prospective directions, emphasizing individualized treatment based on subtypes, novel immunotherapeutic approaches, and thymectomy.

摘要

引言

近年来,重症肌无力(MG)的研究发展迅速。本文旨在阐明过去20年MG相关出版物的特征,并使用文献计量学方法分析新出现的趋势。

方法

从科学网核心合集获取MG文章的信息,并存储在Excel中进行定量分析。使用CiteSpace和VOSviewer进行文献计量分析,以根据国家/地区、机构、期刊和作者对出版物进行可视化展示。

结果

分析共纳入3610篇出版物。美国的出版物数量(NP)和H指数最高。在机构中,牛津大学的NP最高,其次是多伦多大学和杜克大学。观察到国家和机构之间存在密切合作。产出最多的作者是雷纳托·曼泰加扎,其次是扬·J·韦尔舒伦和阿梅莉亚·埃沃利。 发表的关于MG的文章最多,其次是 和 。强度最高的关键词是“神经肌肉传递”,其次是“安全性”和“利妥昔单抗”。共被引分析包括103篇被引至少65次的出版物,分为四个聚类。此外,对123个被引次数超过40次的关键词进行了分析,并分为五个聚类。

结论

这项文献计量分析通过绘制各国或地区、机构、期刊和作者在MG研究中的学术贡献,展示了过去20年的研究框架。该分析还探索了未来趋势和潜在方向,强调基于亚型的个体化治疗、新型免疫治疗方法和胸腺切除术。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c0b/10782526/97a1ef403545/fneur-14-1320344-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c0b/10782526/d29245045a1f/fneur-14-1320344-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c0b/10782526/f86a7948fbe2/fneur-14-1320344-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c0b/10782526/b31c51899521/fneur-14-1320344-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c0b/10782526/8e315a7857de/fneur-14-1320344-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c0b/10782526/223730895c17/fneur-14-1320344-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c0b/10782526/546df2e735ad/fneur-14-1320344-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c0b/10782526/6a9074fabf77/fneur-14-1320344-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c0b/10782526/e0c085901013/fneur-14-1320344-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c0b/10782526/4fd8a549f39c/fneur-14-1320344-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c0b/10782526/ebd3727f3347/fneur-14-1320344-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c0b/10782526/97a1ef403545/fneur-14-1320344-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c0b/10782526/d29245045a1f/fneur-14-1320344-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c0b/10782526/f86a7948fbe2/fneur-14-1320344-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c0b/10782526/b31c51899521/fneur-14-1320344-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c0b/10782526/8e315a7857de/fneur-14-1320344-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c0b/10782526/223730895c17/fneur-14-1320344-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c0b/10782526/546df2e735ad/fneur-14-1320344-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c0b/10782526/6a9074fabf77/fneur-14-1320344-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c0b/10782526/e0c085901013/fneur-14-1320344-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c0b/10782526/4fd8a549f39c/fneur-14-1320344-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c0b/10782526/ebd3727f3347/fneur-14-1320344-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c0b/10782526/97a1ef403545/fneur-14-1320344-g011.jpg

相似文献

1
Mapping current trends and hotspots in myasthenia gravis from 2003 to 2022: a bibliometric analysis.2003年至2022年重症肌无力的当前趋势和热点图谱:一项文献计量分析
Front Neurol. 2023 Dec 28;14:1320344. doi: 10.3389/fneur.2023.1320344. eCollection 2023.
2
Knowledge mapping of targeted immunotherapy for myasthenia gravis from 1998 to 2022: A bibliometric analysis.从 1998 年到 2022 年针对重症肌无力的靶向免疫治疗的知识图谱:文献计量分析。
Front Immunol. 2022 Sep 29;13:998217. doi: 10.3389/fimmu.2022.998217. eCollection 2022.
3
Knowledge mapping of global trends for myasthenia gravis development: A bibliometrics analysis.全球重症肌无力发展趋势的知识图谱:文献计量分析。
Front Immunol. 2023 Mar 2;14:1132201. doi: 10.3389/fimmu.2023.1132201. eCollection 2023.
4
Research hotspots and trends of bone defects based on Web of Science: a bibliometric analysis.基于科学网的骨缺损研究热点与趋势:文献计量分析
J Orthop Surg Res. 2020 Oct 8;15(1):463. doi: 10.1186/s13018-020-01973-3.
5
Worldwide research tendency and hotspots on hip fracture: a 20-year bibliometric analysis.全球髋部骨折研究趋势和热点:20 年文献计量分析。
Arch Osteoporos. 2021 Apr 17;16(1):73. doi: 10.1007/s11657-021-00929-2.
6
Bibliometric analysis of global research trends on male osteoporosis: a neglected field deserves more attention.男性骨质疏松症全球研究趋势的文献计量分析:一个被忽视的领域值得更多关注。
Arch Osteoporos. 2021 Oct 11;16(1):154. doi: 10.1007/s11657-021-01016-2.
7
Research trends in endoscopic applications in early gastric cancer: A bibliometric analysis of studies published from 2012 to 2022.早期胃癌内镜应用的研究趋势:对2012年至2022年发表的研究进行的文献计量分析
Front Oncol. 2023 Apr 11;13:1124498. doi: 10.3389/fonc.2023.1124498. eCollection 2023.
8
Global research status of anterior cruciate ligament reconstruction: a bibliometric analysis.前交叉韧带重建的全球研究现状:一项文献计量分析。
EFORT Open Rev. 2022 Dec 21;7(12):808-816. doi: 10.1530/EOR-21-0065.
9
Articles on hemorrhagic shock published between 2000 and 2021: A CiteSpace-Based bibliometric analysis.2000年至2021年间发表的关于失血性休克的文章:基于CiteSpace的文献计量分析
Heliyon. 2023 Aug 7;9(8):e18840. doi: 10.1016/j.heliyon.2023.e18840. eCollection 2023 Aug.
10
Research trends in readiness for hospital discharge between 2002 and 2021: A bibliometric analysis.2002 年至 2021 年出院准备度研究趋势:文献计量分析。
Nurs Open. 2023 Dec;10(12):7676-7693. doi: 10.1002/nop2.2009. Epub 2023 Sep 29.

本文引用的文献

1
Efficacy of innovative therapies in myasthenia gravis: A systematic review, meta-analysis and network meta-analysis.创新性疗法在重症肌无力中的疗效:系统评价、荟萃分析和网络荟萃分析。
Eur J Neurol. 2023 Dec;30(12):3854-3867. doi: 10.1111/ene.15872. Epub 2023 May 30.
2
Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension.抗乙酰胆碱受体抗体阳性全身型重症肌无力成人患者使用拉那利尤单抗的长期疗效和安全性:III 期 CHAMPION MG 开放标签扩展研究结果。
J Neurol. 2023 Aug;270(8):3862-3875. doi: 10.1007/s00415-023-11699-x. Epub 2023 Apr 27.
3
Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis.
瑞夫利珠单抗在全身型重症肌无力患者中的药代动力学和药效学。
J Neurol. 2023 Jun;270(6):3129-3137. doi: 10.1007/s00415-023-11617-1. Epub 2023 Mar 9.
4
Comparison of Fixed and Live Cell-Based Assay for the Detection of AChR and MuSK Antibodies in Myasthenia Gravis.固定细胞和活细胞检测在重症肌无力乙酰胆碱受体和肌肉特异性激酶抗体检测中的比较。
Neurol Neuroimmunol Neuroinflamm. 2022 Oct 21;10(1). doi: 10.1212/NXI.0000000000200038. Print 2023 Jan.
5
Poor responses and adverse outcomes of myasthenia gravis after thymectomy: Predicting factors and immunological implications.胸腺瘤切除术后重症肌无力疗效不佳和不良预后:预测因素和免疫学意义。
J Autoimmun. 2022 Oct;132:102895. doi: 10.1016/j.jaut.2022.102895. Epub 2022 Aug 27.
6
Rituximab in myasthenia gravis: efficacy, associated infections and risk of induced hypogammaglobulinemia.利妥昔单抗治疗重症肌无力:疗效、相关感染和引起低丙种球蛋白血症的风险。
Neuromuscul Disord. 2022 Aug;32(8):664-671. doi: 10.1016/j.nmd.2022.06.006. Epub 2022 Jun 21.
7
Eculizumab versus rituximab in generalised myasthenia gravis.依库珠单抗与利妥昔单抗治疗全身性重症肌无力的疗效比较。
J Neurol Neurosurg Psychiatry. 2022 May;93(5):548-554. doi: 10.1136/jnnp-2021-328665. Epub 2022 Mar 4.
8
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.依氟鸟氨酸苷单抗在全身性重症肌无力患者中的安全性、疗效和耐受性(ADAPT):一项多中心、随机、安慰剂对照、3 期临床试验。
Lancet Neurol. 2021 Jul;20(7):526-536. doi: 10.1016/S1474-4422(21)00159-9.
9
Benefit and danger from immunotherapy in myasthenia gravis.免疫疗法治疗重症肌无力的获益和风险。
Neurol Sci. 2021 Apr;42(4):1367-1375. doi: 10.1007/s10072-021-05077-6. Epub 2021 Feb 5.
10
Severe worsening of myasthenic symptoms after the eculizumab discontinuation.停药后肌无力症状严重恶化。
J Neuroimmunol. 2020 Dec 15;349:577424. doi: 10.1016/j.jneuroim.2020.577424. Epub 2020 Oct 9.